Health events with various strategies*
| Screening strategy | Health event; no. per 10 000 screened† | HCV-related deaths prevented v. “no screening” | ||
|---|---|---|---|---|
| Decompensated cirrhosis | Hepatocellular carcinoma | HCV-related liver death | ||
| Age 25–64 yr | ||||
| No screening | 24 | 15 | 35 | – |
| Screen and treat with PEG IFN+RBV | 18 | 12 | 26 | 9 |
| Screen and treat with simeprevir+PEG IFN+RBV (G1), SOF+RBV (G2/3) or PEG IFN+RBV (G4/5/6) | 14 | 7 | 18 | 18 |
| Screen and treat with interferon-free DAA (G1), SOF+RBV (G2/3) or PEG IFN+RBV (G4/5/6) | 13 | 7 | 18 | 18 |
| Age 45–64 yr | ||||
| No screening | 29 | 20 | 44 | – |
| Screen and treat with PEG IFN+RBV | 23 | 17 | 35 | 9 |
| Screen and treat with simeprevir+PEG IFN+RBV (G1), SOF+RBV (G2/3) or PEG IFN+RBV (G4/5/6) | 20 | 8 | 24 | 20 |
| Screen and treat with interferon-free DAA (G1), SOF+RBV (G2/3) or PEG IFN+RBV (G4/5/6) | 18 | 8 | 23 | 21 |
Note: DAA = direct-acting antiviral agent; G1 = genotype 1; G2/3: = genotype 2 or 3; G4/5/6 = genotype 4, 5 or 6; HCV = hepatitis virus C; PEG IFN+RBV = pegylated interferon plus ribavirin; SOF+RBV = sofosbuvir plus ribavirin.
↵* According to the simulation, for every 10 000 people screened, about 63 cases of HCV would be identified. Of these cases, 37 (59%) would be eligible for treatment. Identifying these 37 cases by screening and treating them would prevent, over the lifetime of the cohort, 6 cases of decompensated cirrhosis, 3 cases of hepatocellular carcinoma and 9 HCV-related deaths if PEG IFN+RBV were used for treatment (relative to no screening) or 11 cases of decompensated cirrhosis, 8 cases of hepatocellular carcinoma and18 HCV-related deaths if DAAs were used for treatment (relative to no screening).
↵† Values reported in the table have been rounded to whole numbers.